Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

In response to the Ebola virus (EBOV) crisis of 2013-2016, a recombinant vesicular stomatitis virus (VSV)-based EBOV vaccine was clinically tested (NCT02283099). A single-dose regimen of VSV-EBOV revealed a safe and immunogenic profile and demonstrated clinical efficacy. While EBOV-specific immune responses to this candidate vaccine have previously been investigated, limited human data on immunity to the VSV vector are available. Within the scope of a phase 1 study, we performed a comprehensive longitudinal analysis of adaptive immune responses to internal VSV proteins following VSV-EBOV immunization. While no preexisting immunity to the vector was observed, more than one-third of subjects developed VSV-specific cytotoxic T-lymphocyte responses and antibodies.

Original publication

DOI

10.1093/infdis/jiy565

Type

Journal article

Journal

The Journal of infectious diseases

Publication Date

01/2019

Volume

219

Pages

556 - 561

Addresses

First Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg.

Keywords

VSV-Ebola Consortium (VEBCON), Humans, Vesiculovirus, Vaccines, Synthetic, Ebola Vaccines, Longitudinal Studies, Antibody Formation, Immunity, Cellular, Adult